In NSCLC cells, PPARγ activation by KR-62980, a novel PPARγ agonist, or rosiglitazone, enhances reactive oxygen species (ROS) generation through proline oxidase (POX), resulting in the induction of apoptosis [40]. This evidence concerns the gene PPARG and non-small cell lung carcinoma.